Last reviewed · How we verify

Mundipharma K.K. — Portfolio Competitive Intelligence Brief

Mundipharma K.K. pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Buprenorphine Transdermal System Buprenorphine Transdermal System marketed
Pralatrexate injection Pralatrexate injection phase 3 Antifolate antimetabolite Dihydrofolate reductase (DHFR), folate receptor, reduced folate carrier Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Allist Pharmaceuticals, Inc. · 1 shared drug class
  2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
  3. Radboud University Medical Center · 1 shared drug class
  4. Shanghai Miracogen Inc. · 1 shared drug class
  5. The First Affiliated Hospital with Nanjing Medical University · 1 shared drug class
  6. Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Mundipharma K.K.:

Cite this brief

Drug Landscape (2026). Mundipharma K.K. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mundipharma-k-k. Accessed 2026-05-16.

Related